Allogeneic Mesenchymal Stromal Cells

Phase 1Cell therapy

Allogeneic Mesenchymal Stromal Cells is one of 55 biologic programs targeting Viral Pneumonia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral PneumoniaActive, not recruiting

XerostomiaActive, not recruiting

Septic ShockActive, not recruiting

Viral PneumoniaPhase 1

Active, not recruiting

XerostomiaPhase 1

Active, not recruiting

Septic ShockPhase 1

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Preclinical

2 2

Intropin

Pfizer

Preclinical

2 3

Zyvox

Pfizer

Preclinical

1 4

Doribax

Spravato

2 6

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 7

Glucophage

EMD Serono

Preclinical

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viral Pneumonia1 trial

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

Withdrawn·MMedical University of South Carolina·Phase 1·NCT05286255

Septic Shock1 trial

Cellular Immunotherapy for Septic Shock: A Phase I Trial

Completed·OOttawa Hospital Research Institute·Phase 1·NCT02421484·9 enrolled

Mesenchymal Stem Cell1 trial

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

Withdrawn·MMolly Gallogly·Phase 2·NCT05333029

Xerostomia1 trial

Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells

Completed·IInstitute of Oncology Ljubljana·Phase 1·NCT07431645·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allogeneic Mesenchymal Stromal Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogeneic Mesenchymal Stromal Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogeneic Mesenchymal Stromal Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: OOttawa Hospital Research Institute

Allogeneic Mesenchymal Stromal Cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viral Pneumonia1 trial

Septic Shock1 trial

Mesenchymal Stem Cell1 trial

Xerostomia1 trial

References

Drug Info

Quick Facts

Related News